In vitro and in vivo effects of dantrolene on carbonic anhydrase enzyme activities

Biological and Pharmaceutical Bulletin

Volumn 27, Issue 5, 2004, Pages 613-616

  Gülçin, Ilhami ^a   Beydemir, Sükrü ^a   Büyükokuroǧlu, Mehmet Emin ^a  

^a ATATÜRK UNIVERSITY   (Turkey)

Author keywords

Carbonic anhydrase; Dantrolene; Erythrocyte; Human; Rat

Indexed keywords

CARBONATE DEHYDRATASE; DANTROLENE; HYDROLYASE; SULFANILAMIDE DERIVATIVE; TYROSINE; ENZYME INHIBITOR;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; ERYTHROCYTE; HUMAN; HYDRATION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT; RAT STRAIN; ANIMAL; DOSE RESPONSE; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CARBONIC ANHYDRASES; DANTROLENE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; ERYTHROCYTES; HUMANS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 16644383093     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.27.613     Document Type: Article

References (31)

1. Beydemir Ş., Çiftçi M., Küfrevioǧlu Ö. İ., Büyükokuroǧlu M. E., Biol. Pharm. Bull., 25, 966-969 (2002).
2. Beydemir Š., Gülçin İ., J. Enz. Inhib. Med. Chem. (in press) (2004).
3. Parkkila A. K., Scarim A. L., Parkkila S., Waheed A., Corbett J. A., Sly W. S., J. Biol. Chem., 273, 24620-24623 (1998).
4. Mori K., Ogawa Y., Ebihara K., Tamura N., Tashiro K., Kuwahara T., J. Biol. Chem., 274, 15701-15705 (1999).
5. Supuran C. T., Briganti F., Tilli S., Chegwidden R., Scozzafava A., Bioorg. Medicinal Chem., 9, 703-714 (2001).
6. Beydemir Ş., Gülçin İ., J. Anim. Vet. Adv., 2, 143-146 (2003).
7. Parui R., Gambir K. K., Mehrotra P. P., Biochem. Int., 23, 779-789 (1991).
8. Parui R., Gambir K. K., Cruz I., Hosten A. O., Biochem. Int., 26, 809-820 (1992).
9. Hannedoeche T., Lazaro M., Delgado A. G., Boitard C., Lacour B., Grünfeld J. P., Clin. Sci., 81, 457-464 (1991).
10. Miller R. D., "Basic and Clinical Pharmacology," ed. by Katzung B. G., Appletion and Lange, U.S.A., 1989, pp. 323-333.
11. Taylor P., "Goodman and Gilman's the Pharmacolgical Basis of Therapeutics," ed. by Hardman J. G., Limbird L. E., McGraw Hill, U.S.A., 2001, pp. 193-213.
12. Nasu T., Osaka H., Shibata H., Gen. Pharmacol., 27, 513-517 (1996).
13. Büyükokuroǧlu M. E., Gülçin İ., Oktay M., Küfrevioǧlu Ö. İ., Pharmacol. Res., 44, 491-494 (2001).
14. Büyükokuroǧlu M. E., Taysi S., Polat F., Göçer F., Pharmacol. Res., 45, 421-425 (2002).
15. Wei H., Perry D. C., J. Neurochem., 67, 2390-2398 (1996).
16. Gepdiremen A., Düzenli S., Hacimüftüoǧlu A., Süleyman H., Öztaş S., Pharmacol. Res., 43, 241-244 (2001).
17. Yamagishi F., Komoda T., Ohnishi K., Itoh S., Res. Commun. Chem. Pathol. Pharmacol., 82, 237-240 (1993).
18. Büyükokuroǧlu M. E., Taysi S., Koç M., Bakan N., Cell Biochem. Funct., 21, 127-131 (2003).
19. Arslan O., Nalbantoǧlu B., Demir N., Özdemir H., Küfrevioǧlu Ö. İ., Tr. J. Med. Sci., 26, 163-166 (1996).
20. Wilbur K. M., Anderson N. G., J. Biol. Chem., 176, 147-154 (1948).
21. Bülbül M., Hisar O., Beydemir Ş., Çiftçi M., Küfrevioǧlu Ö. İ., J. Enz. Inhib. Med. Chem., 18, 371-375 (2003).
22. Beydemir Ş., Çiftçi M., Özmen İ., Büyükokuroǧlu M. E., Özdemir H., Küfrevioǧlu Ö. İ., Pharmacol. Res., 42, 187-191 (2000).
23. Çiftçi M., Küfrevioǧlu Ö. İ., Gündoǧdu M., Özmen İ., Pharmacol. Res., 41, 109-113 (2000).
24. Bradford M. M., Anal. Biochem., 72, 248-251 (1976).
25. Laemmli D. K., Nature (London), 227, 680-683 (1970).
26. Dogson S. J., "The Carbonic Anhydrases," ed. by Dodgson S. J., Tashian R. E., Gros G., Carter N. D., Plenum Press, New York, 1991, pp. 3-14.
27. Jackson E. K., "Goodman and Gilman's The Pharmacolgical Basis of Therapeutics," ed. by Hardman J. G., Limbird L. E., McGraw Hill, U.S.A., 2001, pp. 757-787.
28. Moynihan J. B., Ennis S., Biochem. J., 272, 553-556 (1990).
29. Wistrand P. J., Lindqvist A., "Design of Carbonic Anhydrase Inhibitors and the Relationship between the Pharmacodynamics and Pharmacokinetics of Acetazolamide," ed. by Botrè F., Gros G., Storey B. T., VCH Verlagsgesellschaft, Weinheim, 1991, pp. 352-374.
30. Meyler W. J., Mols-Thurkow I., Scaf A. H., Sargo S., Wesseling H., Eur. J. Pharmacol., 53, 335-342 (1979).
31. Berkow R., "The Merck Manuel of Diagnosis and Therapy," 15th ed., Merck & Co. Inc., U.S.A., 1987, pp. 2386-2388.